Demyelination and Remyelination in Multiple Sclerosis (MS) Detected by Brain Amyloid PET-CT

Launched by ISTITUTI CLINICI SCIENTIFICI MAUGERI SPA · Mar 23, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how different types of brain imaging, specifically PET and MRI scans, can help understand the changes in the brain of people with multiple sclerosis (MS). The goal is to find out if these imaging techniques can identify areas of the brain that show signs of chronic inflammation, recent inflammation, or areas that appear inactive. The researchers will also analyze blood samples to look for specific proteins and factors that may be related to nerve health and inflammation.

To join the study, participants must be diagnosed with either progressive MS (which includes both primary and secondary forms) or relapsing-remitting MS. However, individuals with severe disabilities, cognitive impairments, or certain medical conditions that could affect their participation will not be eligible. Participants can expect to undergo brain scans and provide blood samples, helping researchers learn more about MS and potentially improve treatments in the future. This study is currently recruiting individuals aged 18 to 65, regardless of gender.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • progressive stage of multiple sclerosis (both secondary and primary, SMP)
• • patients in relapsing-remitting multiple sclerosis (RRMS)
• Exclusion Criteria:
• • a disability greater than 7
• • patients with a cognitive impairment interfering with full study participation (Minimental score less than 24)
• • patients with internal medical problems that in the opinion of the investigator may interfere with full participation and collaboration
• • inability to undergo MRI or PET examinations
• • ongoing pregnancy and lactation